Author

C. Van den Eynde

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

B. Autran· 1 shared C. Buyck· 1 shared C. Hamimi· 1 shared C. Katlama· 1 shared D. Boden· 1 shared D. Bojkova· 1 shared D. Jochmans· 1 shared D. M. Margolis· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

B. Autran

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A truncated HIV Tat demonstrates potent and specific latency reversal activity

E. Van Gulck, M. Pardons, E. Nijs, N. Verheyen, K. Dockx, C. Van Den Eynde, E. Battivelli, J. Vega, E. Florence, B. Autran, N. Archin, D. M. Margolis, C. Katlama, C. Hamimi, I. Van Den Wyngaert, , D. Boden

The paper demonstrates that a truncated HIV Tat protein and mRNA can reactivate HIV-1 in latently infected T-cells as effectively as Phorbol 12-Myristate 13-Acetate without T-cell activation or significant transcriptome changes.

bioRxiv · Mar 2, 2023 · PreprintCell Biology

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

W. Chiu, L. Verschueren, C. Van den Eynde, C. Buyck, S. De Meyer, D. Jochmans, D. Bojkova, S. Ciesek, J. Cinatl, S. De Jonghe, P. Leyssen, J. Neyts, M. Van Loock, E. Van Damme

The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.

bioRxiv · Feb 2, 2022Immunology